Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Oxford University spin-off company Vaccitech has raised $27.1 million in series A funding to advance its universal flu vaccine and cancer vaccine programs. The flu vaccine, based on proteins conserved across all influenza A strains, is currently in a Phase IIb trial with over 800 people. Programs for four other infectious diseases are in various stages of development, and a Phase II trial for a prostate cancer vaccine will begin this year. Investors include GV (formerly Google Ventures), Sequoia China, Oxford Sciences Innovation, and Neptune Ventures.
This article has been sent to the following recipient: